Extract from M&A Insights

The below story was originally featured in our daily M&A Insights Newsletter. Selected stories, including this one, are posted to our website with some weeks of delay.
AlzeCure is preparing SEK 250m IPO on First North
November 7, 2018

AlzeCure, a pharmaceutical company focusing on curing Alzheimer and brain diseases, has published its prospectus prior to its IPO. AlzeCure will raise a maximum of SEK 250m with the IPO, corresponding to a valuation of SEK 529m if the IPO is fully subscribed. AlzeCure reported a turnover of SEK 2.8m and EBIT of SEK -23m in the first nine months of 2018 and has two phase-1 studies in the pipeline.

ⓘ This story was originally featured in our daily M&A Insights newsletter.
Our insights have been covered by: